Core Viewpoint - Baotai (688177) reported a revenue of 442 million yuan for the first half of 2025, marking a year-on-year increase of 9.84%, while the net profit attributable to shareholders was -125 million yuan, an improvement from -237 million yuan in the same period last year, indicating a reduction in losses [1] Financial Performance - The company achieved an operating income of 442 million yuan in the first half of 2025, reflecting a growth of 9.84% compared to the previous year [1] - The net profit attributable to shareholders was -125 million yuan, which is an improvement from -237 million yuan in the same period last year, showing a reduction in losses [1] Market Expansion - During the reporting period, the company actively expanded its market presence, with domestic sales of Adalimumab injection (Ge Li Li) and Tocilizumab injection (Shi Rui Li) steadily increasing compared to the same period last year [1]